Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 5/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.48 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.48 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.47 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4969336 | 1.00 | PTGER4 (0.48) | PTGER4PTGER2PTGER3PTGER1LTB4R | |
| SCHEMBL4969557 | 0.94 | HDAC8 (0.46) | PTGER4PTGER2PTGER3PTGER1LTB4R | |
| SCHEMBL4969554 | 0.94 | HDAC8 (0.46) | PTGER4PTGER2PTGER3PTGER1LTB4R | |
| SCHEMBL4969850 | 0.85 | AOC3 (0.46) | LTB4R2AOC3 | |
| SCHEMBL4969846 | 0.85 | AOC3 (0.46) | LTB4R2AOC3 | |
| SCHEMBL5654914 | 0.84 | KDM4E (0.55) | PTGER4PTGER2PTGER3PTGER1LTB4R | |
| SCHEMBL5654907 | 0.84 | KDM4E (0.55) | PTGER4PTGER2PTGER3PTGER1LTB4R | |
| SCHEMBL4969521 | 0.83 | PTGER4 (0.47) | PTGER4PTGER2PTGER3PTGER1LTB4R | |
| SCHEMBL4970394 | 0.81 | AOC3 (0.52) | KDM4EAOC3 | |
| SCHEMBL4970387 | 0.81 | AOC3 (0.52) | KDM4EAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781274-B1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2008-11-05 | — | — | EP | disclosed |
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-06 | — | — | US | disclosed |
| EP-1781274-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018325-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | PTGER4 424/4885PTGER2 405/4885PTGER3 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.